|
Hooper, David C; Jacoby, George A (2016) Topoisomerase Inhibitors: Fluoroquinolone Mechanisms of Action and Resistance. Cold Spring Harb Perspect Med 6:
|
|
Hooper, David C; Jacoby, George A (2015) Mechanisms of drug resistance: quinolone resistance. Ann N Y Acad Sci 1354:12-31
|
|
Jacoby, George; Cattoir, Vincent; Hooper, David et al. (2008) qnr Gene nomenclature. Antimicrob Agents Chemother 52:2297-9
|
|
Truong-Bolduc, Que Chi; Hooper, David C (2007) The transcriptional regulators NorG and MgrA modulate resistance to both quinolones and beta-lactams in Staphylococcus aureus. J Bacteriol 189:2996-3005
|
|
Strahilevitz, Jacob; Onodera, Yoshikuni; Hooper, David C (2006) An improved expression plasmid for affinity purification of Staphylococcus aureus gyrase A subunit. Protein Expr Purif 47:10-5
|
|
Strahilevitz, Jacob; Robicsek, Ari; Hooper, David C (2006) Role of the extended alpha4 domain of Staphylococcus aureus gyrase A protein in determining low sensitivity to quinolones. Antimicrob Agents Chemother 50:600-6
|
|
Truong-Bolduc, Que Chi; Strahilevitz, Jacob; Hooper, David C (2006) NorC, a new efflux pump regulated by MgrA of Staphylococcus aureus. Antimicrob Agents Chemother 50:1104-7
|
|
Strahilevitz, Jacob; Hooper, David C (2005) Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin. Antimicrob Agents Chemother 49:1949-56
|
|
Strahilevitz, Jacob; Truong-Bolduc, Que Chi; Hooper, David C (2005) DX-619, a novel des-fluoro(6) quinolone manifesting low frequency of selection of resistant Staphylococcus aureus mutants: quinolone resistance beyond modification of type II topoisomerases. Antimicrob Agents Chemother 49:5051-7
|
|
Hooper, David C (2005) Efflux pumps and nosocomial antibiotic resistance: a primer for hospital epidemiologists. Clin Infect Dis 40:1811-7
|
Showing the most recent 10 out of 43 publications
